Discovery of New Medicines

The Textbook of Pharmaceutical Medicine

Volumn , Issue , 2013, Pages 1-31

  Ribeill, Yves J ^a  

^a SCYNEXIS Inc   (United States)

Author keywords

CNS; Disease; Drug discovery; FBDD; Immune; Inflammation; Marketed; Metabolic; Orphan; Strategy; Virus

Indexed keywords

EID: 84887234917     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118532331.ch1     Document Type: Chapter

References (232)

1. Raju TN. The Nobel chronicles. 1998: Robert Francis Furchgott (b 1911), Louis J Ignarro (b 1941), and Ferid Murad (b 1936). Lancet. 2000; 356: 346.
2. Boolell BM, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996; 8 (2): 47-52.
3. Terrett NK. Sildenafil (Viagra), a potent and selective inhibitor of Type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg Med Chem Lett. 1996; 6 (15): 1819-24.
4. Bunnage ME. Getting pharmaceutical R& D back on target. Nat Chem Biol. 2011; 7: 335-9.
5. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R & D productivity: the pharmaceutical industry ' s grand challenge. Nat Rev Drug Discov. 2010; 9: 203-14.
6. Herper M. 2011. The decline of pharmaceutical research, measured in new drugs and dollars. Available from: http://www.forbes.com/sites/matthewherper/ 2011/06/27/the-decline-of-pharmaceuticalresearchmeasured-in-new-drugs-an d-dollars/ (accessed 5 November 2012).
7. Bronson J, Dhar M, Ewing W, Lonberg N. To market, to market. Annu Rep Med Chem. 2011; 46: 433.
8. Hegde S, Schmidt M. To market, to market. Annu Rep Med Chem. 2009; 44: 577.
9. Hegde S, Schmidt M, To market, to market. Annu Rep Med Chem. 2010; 45: 467.
10. Wyatt PG. The emerging academic drug-discovery sector. Future Med Chem. 2009; 1 (6): 1013-7.
11. Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical R & D. Nat Rev Drug Discov. 2011; 10: 428-38.
12. Chrysant SG, Chyrsant GS, Dimas B. Current and future status of beta-blockers in the treatment of hypertension. Clin Cardiol. 2008; 31: 249-52.
13. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R & D effi-ciency. Nat Rev Drug Discov. 2012; 11: 191-200.
14. Mullard A. 2010 FDA drug approvals. Nat Rev Drug Discov. 2011; 10: 82-5.
15. Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc. 1963; 85: 2149-54.
16. Long A. Parallel chemistry in the 21st century. Curr Protoc Pharmacol. 2012. 2012 Sep;Chapter 9:Unit9.16. doi: 10.1002/0471141755.ph0916s58.
17. Geysen HM, Meloen RH, Berteling SJ. Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proc Natl Acad Sci U S A. 1984; 81: 3998-4002.
18. Houghten RA. General method for the rapid solidphase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids (simultaneous multiple-peptide synthesis). Proc Natl Acad Sci U S A. 1985; 82: 5131-5.
19. Furka A, Sebestyen F, Asgedom M, Dibo G. General method for rapid synthesis of multicomponent peptide mixtures. Int J Pept Protein Res. 1991; 37: 487-93.
20. Furka A. History of combinatorial chemistry. Drug Dev Res. 1995; 36: 1-12.
21. Lam KS, Salmon SE, Hersh EM, Hruby VJ, Kazmierski WM, Knapp RJ. A new type of synthetic peptide library for identifying ligand-binding activity. Nature. 1991; 354: 82-4.
22. Ohlmeyer MHJ, Swanson RN, Dillard LW, Reader JC, Asouline G, Kobayashi R, et al. Complex synthetic chemical libraries indexed with molecular tags. Proc Natl Acad Sci U S A. 1993; 90: 10922-6.
23. Coffen DL, Luithle JEA. Introduction to combinatorial chemistry. In: Nicolaou KC, Hanko R, Hartwig W, editors. Handbook of combinatorial chemistry: drugs, catalysts, materials. Vol. 1. Weinheim: Wiley; 2002. pp. 10-23.
24. Tan D. Diversity-oriented synthesis: exploring the intersections between chemistry and biology. Nat Chem Biol. 2005; 1: 74-84.
25. Feher M, Schmidt JM. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem Inf Comput Sci. 2003; 43: 218-27.
26. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2007; 5: 835-44.
27. Bunin BA, Ellman JA. A general and expedient method for the solid-phase synthesis of 1,4-benzodiazepine derivatives. J Am Chem Soc. 1992; 114: 10997-8.
28. Ruijter E, Scheffelaar R, Orru RVA. Multicomponent reaction design in the quest for molecular complexity and diversity. Angew Chem Int Ed. 2011; 50: 6234-46.
29. Schreiber SL. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science. 2000; 287: 1964-9.
30. Curran DP, Moura-Letts G, Pohlman M. Solution -phase mixture synthesis with fluorous tagging en route: total synthesis of an eight-member stereoisomer library of passifloricins. Angew Chem Int Ed. 2006; 45: 2423-6.
31. Curran DP, Zhang Q, Richard C, Lu H, Gudipati V, Wilcox CS. Total synthesis of a 28-member stereoisomer library of murisolins. J Am Chem Soc. 2006; 128: 9561-73.
32. Kappe CO. Controlled microwave heating in modern organic synthesis. Angew Chem Int Ed. 2004; 43: 6250-84.
33. Berger M, Cramer J, Hinz M, Mertens C, Miculka C, Newton T, et al. Learning to relate structural space to property space. In: Selzer PM, editor. Antiparasitic and antibacterial drug discovery: from molecular targets to drug candidates. Weinheim: Wiley; 2009. p. 135-8.
34. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997; 23: 3-25.
35. Lipinski C, Hopkins A. Navigating chemical space for biology and medicine. Nature. 2004; 432: 855-61.
36. Köster H, Craan T, Brass S, Herhaus C, Zentgraf M, Neumann L, et al. A small nonrule of 3 compatible fragment library provides high hit rate of endothiapepsin crystal structures with various fragment chemotypes. J Med Chem. 2011; 54 (22): 7784-96.
37. Kuntz ID, Chen K, Sharp KA, et al. The maximal affinity of ligands. Proc Natl Acad Sci U S A. 1999; 96: 9997-10002.
38. Barelier S, Pons J, Gehring K, et al. Ligand specificity in fragment-based drug design. J Med Chem. 2010; 53 (14): 5256-66.
39. Chen IJ, Hubbard RE. Lessons for fragment library design: analysis of output from multiple screening campaigns. J Comput Aided Mol Des. 2009; 23 (8): 603-20.
40. Erlanson DA. Introduction to fragment-based drug discovery. In: Davies TG, Hyvönen M, editors. Fragment-based drug discovery and X-ray crystallography. Topics in current chemistry 317. Berlin Heidelberg: Springer-Verlag; 2012. pp. 1-32.
41. Mayer M, Meyer B. Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J Am Chem Soc. 2001; 123: 6108-17.
42. Dalvit C, Fogliatto G, Stewart A, Veronesi M, Stockman B. WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability. J Biomol NMR. 2001; 21: 349-59.
43. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. Discovering high-affinity ligands for proteins: SAR by NMR. Science. 1996; 274 (5292): 1531-4.
44. Jordan JB, Poppe L, Xia X, Cheng AC, Sun Y, Michelsen K, et al. Fragment based drug discovery: practical implementation based on 19F NMR spectroscopy. J Med Chem. 2012; 55 (2): 678-87.
45. Vulpetti A, Hommel U, Landrum G, et al. Design and NMR-based screening of LEF, a library of chemical fragments with different local environment of fluorine. J Am Chem Soc. 2009; 131 (36): 12949-59.
46. Wyss DF, Wang Y-S, Eaton HL, et al. Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE -1 inhibitors. In: Davies TG, Hyvönen M, editors. Fragment-based drug discovery and X-ray crystallography. Topics in current chemistry 317. Berlin Heidelberg: Springer-Verlag; 2012. pp. 83-114.
47. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989; 244: 359-62.
48. World Health Organization. 2012. Hepatitis C fact sheet No 164. Available from: http://www.who.int/ mediacentre/factsheets/fs164/en/index.html (accessed 5 November 2012).
49. Simmonds P. Variability of hepatitis C virus. Hepatology. 1995; 21: 570-83.
50. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev. 2000; 13: 223-35.
51. Lindenbach BD, Rice CM. Unraveling hepatitis C virus replication from genome to function. Nature. 2005; 436: 933-8.
52. Yu CI, Chiang BL. A new insight into hepatitis C vaccine development. J Biomed Biotechnol. 2010; 2012: 548280.
53. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005; 436: 967-72.
54. Venkatraman S, Bogen SL, Arasappan A, et al. Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1 -dimethylethyl)amino] carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6 -dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J Med Chem. 2006; 49: 6074-86.
55. Sudhakar A, Dahanukar V, Zavialov IA, et al. Process and intermediates for the preparation of (1R,2S,5S) -N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl] -3-[(2S)-2-[[[[1,1-dimethylethyl]amino]carbonyl] amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3 -azabicyclo[3.1.0]hexane-2-carboxamide. WO2004113294 A1 (Patent) 2004.
56. Whitehouse Station: Merck & Co.; 2011. Highlights of prescribing information for Vitrelis (boceprevir). Available from: http://www.merck.com/product/usa/ pi_circulars/v/victrelis/victrelis_pi.pdf (accessed 5 No -vember 2012).
57. Tanoury GJ, Chen M, Cochran JE. Preparation of peptides for treatment of hepatitis C virus. WO 2007022459 A2 (Patent) 2007.
58. Cambridge: Vertex Pharmaceuticals Inc.. 2011. Highlights of prescribing information for Incivek (telaprevir). Available from: http://pi.vrtx.com/files/uspi_ telaprevir.pdf (accessed 5 November 2012).
59. Weiss RA. How does HIV cause AIDS? Science. 1993; 260: 1273-9.
60. Atlanta: Centers for Disease Control and Prevention; 1992. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/ 00018871.htm (accessed 5 November).
61. UNAIDS Joint United Nations Programme on HIV/ AIDS, Geneva; 2009. Global facts and figures 09. Available from: http://data.unaids.org/pub/FactSheet/2009/ 20091124_FS_global_en.pdf (accessed 5 November 2012).
62. Reeves JD, Doms RW. Human immunodeficiency virus type 2. J Gen Virol. 2002; 83: 1253-65.
63. Kindt TJ, Goldsby RA, Osborne BA. Chapter 20: AIDS and other immunodeficiencies. In Kindt TJ, Goldsby RA, Osborne BA editors. Kuby immunology, 6th edn. New York: WH Freeman and Company; 2007. pp. 493-524.
64. US Food and Drug Administration, Silver Spring. 2011. Antiretroviral drugs used in the treatment of HIV infection. Available from: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAID SActivities/ucm118915.htm (accessed 5 November 2012).
65. Flexner C. Chapter 50: antiretroviral agents and treatment of HIV infection. In: Goodman LS, Gilman A, editors. Goodman & Gilman ' s the pharmacological basis of therapeutics, 11th edn. New York: McGraw Hill; 2006. pp. 1273-314.
66. Ludovici DW, De Corte BL, Kukla MJ, Ye H, Ho CY, Lichtenstein MA, et al. Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues. Bioorg Med Chem Lett. 2001; 11: 2235-9.
67. Joshi S, Maikap GC, Titirmare S, et al. An improved synthesis of etravirine. Org Process Res Dev. 2010; 14: 657-60.
68. Gurjar MK, Maikap GS, Joshi SG, et al. Process for synthesis of diarylpyrimidine non-nucleoside reverse transcriptase inhibitor. WO 2010150279 A2 (Patent) 2010.
69. Krizmanic I, Dogan J, Marinkovic M, et al. Process for preparation of etravirine. WO 2011017079 A1 (Patent) 2011.
70. Raritan: Tibotec Therapeutics. 2008. Highlights of prescribing information for Intelence (etravirine) Available from: http://www.intelence-info.com/sites/ default/files/pdf/INTELENCE_Booklet_Package_ Insert_hcp.pdf (accessed 5 November 2012).
71. Guillemont J, Pasquier E, Palandjian P, Vernier D, Gaurrand S, Lewi PJ, et al. Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1. J Med Chem. 2005; 48: 2072-9.
72. Schils DPR, Willems JJM, Medaer BPAMJ, et al. Process for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino ]benzonitrile. WO 2004016581 A1 (Patent) 2004.
73. Raritan: Tibotec Therapeutics; 2011. Highlights of prescribing information for Edurant (rilpivirine) [web page on the Internet]. Available from: http:// www.edurant-info.com/hcp/sites/www.edurant-info. com.hcp/files/EDURANT-PI.pdf (accessed 5 November 2012).
74. Racke MK, Lovett-Racke AE, Karandikar NJ. The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology. 2010; 74 (Suppl. 1): S25-30.
75. Lalive PH, Neuhaus O, Benkhoucha M, Burger D, Hohlfeld R, Zamvil SS, et al. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs. 2011; 25: 401.
76. TEVA Pharmaceuticals USA. Full prescribing information (package insert) for Copaxone NDA no. 020622 at Drugs@FDA. 2009.
77. Hayes KC. The use of 4-aminopyridine (fampridine) in demyelinating disorders. CNS Drug Rev. 2004; 10: 295-316.
78. Brinkman V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002; 277: 21453.
79. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002; 296: 346.
80. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010; 362: 387-401.
81. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatru BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010; 362: 402-15.
82. Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo -controlled, multicentre trial. Lancet. 2011; 378: 1179-87.
83. Sucher BJ, Mehlhorn AJ. Alzheimer's disease: practical management of cognitive symptoms. US Pharm. 2007; 32 (6): 45-53.
84. DeSimone EM II, Viereck L. Alzheimer' s disease: increasing numbers, but no cure. US Pharm. 2011; 36 (1): 26-42.
85. Cupp M. Efficacy of dementia drugs and guidelines for use. Pharm Lett. 2008; 24: 240510.
86. Misra RN. NIH translational programs for assisting pre-clinical drug discovery and development. Annu Rep Med Chem. 2010; 45: 361-77.
87. Messer WS Jr. Drugs that target muscarinic cholinergic receptors. In: Buccafusco JJ, editor. Cognitive enhancing drugs. Basel: Birkhäuser Verlag; 2004. pp. 37-45.
88. Benbow JW, Helal CJ, Kung DW, Wager TT. Glycogen Synthase Kinase-3 (GSK-3): a kinase with exceptional therapeutic potential. Annu Rep Med Chem. 2005; 40: 135-47.
89. Gentles RG, Hu S, Dubowchik GM. Recent advances in the discovery of GSK-3 inhibitors and a perspective on their utility for the treatment of Alzheimer ' s disease. Annu Rep Med Chem. 2009; 44: 3-26.
90. Lashinger Erin SR, Steiginga Matthew S, Hieble JP, Leon Lisa A, Gardner Scott D, Nagilla R, et al. AMTB, a TRPM8 channel blocker: evidence in rats for activity in overactive bladder and painful bladder syndrome. Am J Physiol Renal Physiol. 2008; 295: F803-10.
91. Hegde S, Schmidt M. Catumaxomab. Annu Rep Med Chem. 2010; 45: 495-6.
92. Krishnamoorthy S, Lip GY. Antiarrhythmic drugs for atrial fibrillation: focus on dronedarone. Expert Rev Cardiovasc Ther. 2009; 7: 473-81.
93. Bronson J, Dhar M, Ewing W, Lonberg N. To market, to market-2010. Annu Rep Med Chem. 2011; 46: 491-2.
94. Billman GE. Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks K(v)1.5 channels, for the potential treatment of atrial fibrillation. Curr Opin Investig Drugs. 2010; 11: 1048.
95. Hegde S, Schmidt M. To market, to market-2008. Annu Rep Med Chem. 2009; 44: 594-6.
96. Mohiuddin SM, Pepine CJ, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J. 2009; 157: 195.
97. Hegde S, Schmidt M. To market, to market-2008. Annu Rep Med Chem. 2008; 43: 461-3.
98. Newman JH, Kar S, Kirkpatrick P. Ambrisentan. Nat Rev Drug Discov. 2007; B: 697.
99. Hegde S, Schmidt M. To market, to market-2008. Annu Rep Med Chem. 2009; 44: 592-4.
100. Varon J. Treatment of acute severe hypertension: current and newer agents. Drugs. 2008; 68: 283.
101. Bronson J, Dhar M, Ewing W, Lonberg N. To market, to market-2010. Annu Rep Med Chem. 2011; 46: 464-5.
102. Garnock-Jones KP. Ecallantide. In acute hereditary angioedema. Drugs. 2010; 70: 1423.
103. Hegde S, Schmidt M. To market, to market-2008. Annu Rep Med Chem. 2009; 44: 608-10.
104. Bork K, Yasothan U, Kirkpatrick P. Icatibant. Nat Rev Drug Discov. 2008; 7: 801.
105. Hegde S, Schmidt M. To market, to market-2008. Annu Rep Med Chem. 2009; 44: 617-9.
106. Kakar P, Watson T, Lip GHY. Rivaroxaban. Drugs Today. 2007; 43: 129.
107. Hegde S, Schmidt M. To market, to market-2008. Annu Rep Med Chem. 2010; 45: 519-21.
108. Baker WL, White CM. Role of prasugrel, a novel P2Y12 receptor antagonist, in the management of acute coronary syndromes. Am J Cardiovasc Drugs. 2009; 9: 213.
109. Bronson J, Dhar M, Ewing W, Lonberg N. To market, to market-2010. Annu Rep Med Chem. 2011; 46: 488-91.
110. Zhao Z, Winget M. Economic burden of illness of acute coronary syndromes: medical and productivity costs. BMC Health Serv Res. 2011; 11: 35.
111. Bronson J, Dhar M, Ewing W, et al. To market, to market-2010. In: Macor JE, editor. Annual reports in medincinal chemistry. Vol. 46. Oxford, UK: Elsevier; 2011. pp. 480-2.
112. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004; 364: 709-21.
113. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary. Am J Respir Crit Care Med. 2007; 176: 532-55.
114. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3: e442.
115. Vathenen AS, Britton JR, Ebden P, et al. High dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis. 1988; 138: 850-5.
116. Gross NJ, Petty TL, Friedman M, et al. Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease: a three-center study. Am Rev Respir Dis. 1989; 139: 1188-91.
117. Chrystyn H, Mulley BA, Peake MD. Dose response relation to oral theophylline in severe chronic obstructive airways disease. BMJ. 1988; 297: 1506-10.
118. Higgins BG, Powell RM, Cooper S, et al. Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis. Eur Respir J. 1991; 4: 415-20.
119. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002; 166: 1084-91.
120. Jones PW, Willits LR, Burge PS, et al. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J. 2003; 21: 68-73.
121. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet. 2003; 361: 449-56.
122. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003; 21: 74-81.
123. Decramer M, de Bock V, Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996; 153: 1958-64.
124. Decramer M, Lacquet LM, Fagard R, et al. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med. 1994; 150: 11-6.
125. Decramer M, Stas KJ. Corticosteroid-induced myopathy involving respiratory muscles in patients with chronic obstructive pulmonary disease or asthma. Am Rev Respir Dis. 1992; 146: 800-2.
126. Hegde S, Schmidt M. To market, to market-2009. In: Macor JE, editor. Annual reports in medicinal chemistry. Vol. 45. Oxford, UK: Elsevier; 2010. p. 505-7.
127. Davies SL, Castaner J. Indacaterol. Asthma therapy, Treatment of COPD, β 2-Adrenoceptor agonist. Drugs Future. 2005; 30: 1219-24.
128. US Food and Drug Administration. 2011. FDA approves Arcapta Neohaler to treat chronic obstructive pulmonary disease (Press release). 2011. Available from: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm261649.htm (accessed 9 November 2012).
129. Boswell-Smith V, Cazzola M, Page C. Are phosphodiesterase 4 inhibitors just more theophylline? J Allergy Clin Immunol. 2006; 117: 1237-43.
130. Giembycz MA, Field SK. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des Devel Ther. 2010; 4: 147-58.
131. Higgs G. Is PDE4 too difficult a drug target? Curr Opin Investig Drugs. 2010; 11: 495-8.
132. Sanford M. Roflumilast: in chronic obstructive pulmonary disease. Drugs. 2010; 70: 1615-27.
133. EMA. CHMP assessment report. 22 April 2010 EMA/ 464905/2010.
134. Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. Endocr Rev. 1998; 19: 608-24.
135. Bliss M. Rewriting medical history: charles best and the banting and best myth. J Hist Med. 1993; 48: 254.
136. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled Type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008; 31: 1479-84.
137. Pijl H, Ohashi S, Matsuda M, et al. Bromocriptine: a novel approach to the treatment of Type 2 diabetes. Diabetes Care. 2000; 23: 1154-61.
138. Toft-Nielsen M, Madsbad S, Holst J. Determinants of the effectiveness of glucagon-like peptide-1 in Type 2 diabetes. J Clin Endocrinol Metab. 2001; 86: 3853-60.
139. Ryan GJ, Hardy Y. Liraglutide: once-daily GLP-1 agonist for the treatment of Type 2 diabetes. J Clin Pharm Ther. 2011; 36: 260-74.
140. White J. Dipeptidyl peptidase-IV inhibitors: pharmacological profile and clinical use. Clin Diabetes. 2008; 26: 53-7.
141. Peters JU. 11 years of cyanopyrrolidines as DPP-IV inhibitors. Curr Top Med Chem. 2007; 7: 579-95.
142. Wang Y, Senadell N, Rosa E, Castaner R. BI-1356. Drugs Future. 2008; 33: 473-7.
143. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary. Am J Respir Crit Care Med. 2007; 176: 532-55.
144. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994; 272: 1497-505.
145. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999; 340: 1948-53.
146. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999; 353: 1819-23.
147. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000; 320: 1297-303.
148. National Osteoporosis Foundation. Available from: www.NFO.org (accessed 5 November 2012).
149. Zuo C, Huang Y, Bajis R, et al. Osteoblastogenesis regulation signals in bone remodeling. Osteoporos Int. 2012; 23: 1653-63.
150. Silvernam S, Christiansen C. Individualizing osteoporosis therapy. Osteoporos Int. 2012; 23: 797-809.
151. Narváez J, Narváez JA, Gómez-Vaquero C, et al. Lack of response to teriparatide therapy for bisphosphonate -associated osteonecrosis of the jaw. Osteoporos Int. 2012 (Epub ahead of publication. doi: 10.1007/ s00198-012-1918-9).
152. Pazianas M, Abrahamsen B, Wang Y, Russell RG. Incidence of fractures of the femur, including subchanteric, up to 8 years since initiation of oral bisphosphonate therapy; a register-based cohort study using the US MarketScan claims database. Osteoporos Int. 2012 (Epub ahead of publication. doi: 10.1007/ s00198-012-1952-7).
153. Rhee CW, Lee J, Oh S, et al. Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis. Osteoporos Int. 2012; 23: 247-54.
154. Bertolini DR, Nedwin GE, Timothy SB, et al. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature. 1986; 319: 516-8.
155. Iqbal J, Sun L, Zaidi M. Denosumab for the treatment of osteoporosis. Curr Osteoporos Rep. 2010; 8: 163-7.
156. Gray H, Lewis WH. Gray's anatomy of the human body. 20 th ed. New York: Blanchard & Lea; 1918.
157. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesopheal reflux disease. The practice parameters committee of the American College of Gastroenterology. Am J Gastroenterol. 1999; 94: 1431-2.
158. Parsons ME, Ganellin CR. Histamine and its receptors. Br J Pharmacol. 2006; 147: 127-35.
159. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005; 100: 190-200.
160. Metz DC, Vakily M, Dixit T, Mulford D. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther. 2009; 29: 928-37.
161. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007; 369: 1641-57.
162. Business Wire. 2008. APRISO granted marketing approval for maintenance of remission of ulcerative colitis. Available from: http://www.businesswire.com/ news/home/20081031005860/en/APRISO-TM-Granted-FDA-Marketing-Approval-Mai ntenance (accessed 5 November 2012).
163. Hanauer SB, Sandborn W. Management of Crohn ' s disease in adults. Am J Gastroenterol. 2001; 96: 635-43.
164. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat. 2004; 15: 280-94.
165. Goel N, Stephens S. Certolizumab pegol. MAbs. 2010; 2: 137-47.
166. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov. 2003; 2: 52-62.
167. Medical News Today. 2007. HUMIRA ® (Adalimumab) receives FDA approval for treatment of Crohn ' s disease. Available from: http://www.medicalnewstoday.com/ releases/64063.php (accessed 5 November 2012).
168. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A. 1978; 75: 280-4.
169. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998; 391: 806-11.
170. Elabashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001; 411: 494-8.
171. Smith CC, Aurelian L, Reddy MP, et al. Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5. Proc Natl Acad Sci U S A. 1986; 83: 2787-91.
172. Stirchak EP, Summerton JE, Weller DD. Uncharged stereoregular nucleic acid analogs: 2. Morpholino nucleoside oligomers with carbamate internucleoside linkages. Nucleic Acids Res. 1989; 17: 6129-41.
173. Davidson BL, McCray PB Jr. Current prospects for RNA interference-based therapies. Nat Rev Genet. 2011; 12: 329-40.
174. Goodchild J. Therapeutic oligonucleotides. Methods Mol Biol. 2011; 764: 1-15.
175. Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov. 2012; 11: 125-40.
176. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature. 1990; 346: 818-22.
177. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990; 249: 505-10.
178. Ni X, Castanares M, Mukherjee A, Lupold SE. Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem. 2011; 18: 4206-14.
179. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov. 2010; 9: 537-50.
180. Marquis JK, Grindel JM. Toxicological evaluation of oligonucleotide therapeutics. Curr Opin Mol Ther. 2000; 2: 258-63.
181. Cote T, Kelkar A, Xu K, Braun MM, Phillips MI. Orphan products: an emerging trend in drug approvals. Nat Rev Drug Discov. 2010; 9: 84.
182. US Food and Drug Administration. Developing products for rare diseases and conditions. 2012. Available from: http://www.fda.gov/orphan (accessed 5 November 2012).
183. Braun MM, Farag-El-Massah S, Xu K, Cote TR. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov. 2010; 9 (7): 519-22.
184. Scientific Secretariat of The Committee for Orphan Medicinal Products, the European Medicines Agency. European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nat Rev Drug Discov. 2011; 10: 341-9.
185. Wyatt PG. The emerging academic drug-discovery sector. Future Med Chem. 2009; 1 (6): 1013-7.
186. Ohlmeyer M, Zhou M-M. Integration of small -molecule discovery in academic biomedical research. Mt Sinai J Med. 2010; 77: 350-7.
187. National Institutes of Health Center for Translational Therapeutics. Therapeutics for rare and neglected diseases. Available from: http://nctt.nih.gov/trnd/ (accessed 5 November 2012).
188. Erickson-Miller CL, Delorme E, Tian S-S, Hopson CB, Landis AJ, Valoret EI, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009; 27: 424-30.
189. Cook L, Cooper N. Eltrombopag-a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations. Drug Des Devel Ther. 2010; 4: 139-45.
190. Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol. 2010; 85: 174-80.
191. Chouhan JD, Herrington JD. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag. Pharmacotherapy. 2010; 30: 666-83.
192. Department of Health and Human Services. 2008. Eltrombopag olamine. Available from: http://www. accessdata.fda.gov/drugsatfda_docs/appletter/2008/ 022291s000ltr.pdf (accessed 5 November 2012).
193. Nieto M, Calvo G, Hudson I, Feldschreiber P, Brown D, Lee CC, et al. The European Medicines Agency review of eltrombopag (Revolade) for the treatment of adult chronic immune (idiopathic) thrombocytopenic purpura: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Haematologica. 2011; 96: e33-40.
194. McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007; 357: 2227-36.
195. World Health Organization. Accelerating work to overcome the global impact of neglected tropical diseases: a roadmap for implementation. 2010.
196. Trouiller P, Olliaro P, Torreele E, et al. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet. 2002; 22: 2188-94.
197. Moran M, Guzman J, Ropars AL, et al. Neglected disease research and development: how much are we really spending? PLoS Med. 2009; 6: e30.
198. Cohen J, Dibner MS, Wilson A. Development of and access to products for neglected diseases. PLoS ONE. 2010; 5: e10610.
199. Moran M, Guzman J, Henderson K, et al. Neglected disease research and development: is the global financial crisis changing R & D? 2010. Health Policy Division, The George Institute for International Health. Available: http://www.policycures.org/downloads/g-finder_ 2010.pdf. (accessed 5 November 2012).
200. BIO Ventures for Global Health. Developing new drugs and vaccines for neglected diseases of the poor, 2012.
201. Wells TNC, Gutteridge WE. Malaria: new medicines for its control and eradication. In: Palmer M, Wells TNC, editors. Neglected diseases and drug discovery. Cambridge: RSC Publishing; 2011. p. 1-32.
202. Alonso PL, Brown G, Arevalo-Herrera M, et al. A research agenda to underpin malaria eradication. PLoS Med. 2011; 8: e1000406.
203. Villemagne B, Crauste C, Flipo M, et al. Tuberculosis: the drug development pipeline at a glance. Eur J Med Chem. 2012; 51: 1-16.
204. Yun O, Priotto G, Tong J, et al. NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl Trop Dis. 2010; 4: e720.
205. Jacobs RT, Nare B, Wring SA, et al. SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human african trypanosomiasis. PLoS NTD. 2011; 5: e1151.
206. Torreele E, Bourdin Trunz B, Tweats D, et al. Fexinidazole-a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS NTD. 2010; 4: e923.
207. Matlashewski G, Arana B, Kroeger A, et al. Visceral leishmaniasis: elimination with existing interventions. Lancet Infect Dis. 2011; 4: 322-5.
208. Newman DJ, Cragg GM. Natural Products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod. 2012; 75: 311-55.
209. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov. 2005; 4: 206-20.
210. Cordell GA, Colvard MD. Natural products and traditional medicine: turning on a paradigm. J Nat Prod. 2012; 75: 514-25.
211. Mishra BB, Tiwari VK. Natural products in drug discovery: clinical evaluations and investigations. In: Tiwari VK, Mishra BB, editors. Opportunity, challenge and scope of natural products in medicinal chemistry. Research Signpost. pp. 1-62.
212. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; 3: 673-83.
213. Campas C. Drug repositioning summit: finding new routes to success. Drug News Perspect. 2009; 22: 126-8.
214. Tobinick EL. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect. 2009; 22 (2): 119-25.
215. Graul AL, Sorbera L, Pina P, et al. The year ' s new drugs and biologics-2009. Drug News Perspect. 2010; 23: 7-36.
216. US Food and Drug Administration. 2008. Living with fibromyalgia, drugs, approved to manage pain. Available from: http://www.fda.gov/ForConsumers/ ConsumerUpdates/ucm107802.htm (accessed 5 No -vember 2012).
217. US Food and Drug Administration2010. News Re -lease: FDA clears Cymbalta to treat musculoskeletal pain. Available from: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm232708.htm (accessed 5 November 2012).
218. Eli Lilly annual report. 2012. Available from: https:// investor.lilly.com (accessed 5 November 2012).
219. Sleigh SH, Barton CL. Repurposing strategies for therapeutics. Pharm Med. 2010; 24: 151-9.
220. Hajak G, Rodenbeck A, Voderholzer U et al. Doxepin in the treatment of primary insomnia: a placebo -controlled, double-blind, polysomnographic study. J Clin Psychiatry. 2001; 62: 453-63.
221. Somaxon. 2010. Press release: Somaxon announces FDA approval of Silenor (doxepin) for the treatment of insomnia. Available from: http://www.somaxon.com/ media/pdf/press2010/Somaxon-Silenor-FDA-approvalrelease. pdf (accessed 5 November 2012).
222. Doan TL, Pollastri M, Walters MA, Georg GI. The future of drug repositioning: old drugs, new opportunities. Annu Rep Med Chem. 2011; 46: 385-401.
223. Larson RS, Willman C, Sklar LA. Drug repurposing from an academic perspective. Drug Discov Today Ther Strateg. 2011; 8 (3-4): 61-9.
224. Collins FS. Mining for therapeutic gold. Nat Rev Drug Discov. 2011; 10: 397.
225. Xu K, Cote TR. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases. Brief Bioinform. 2011; 12: 341-5.
226. Huang R, Southall N, Wang Y, Yasgar A, Shinn P, Jadhav A, et al. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med. 2011; 3: 80ps16.
227. Smith RB. Repositioned drugs: integrating intellectual property and regulatory strategies. Drug Discov Today Ther Strateg. 2011; 8 (3-4): 131-7.
228. Tralau-Stewart CJ, Wyatt CA, Kleyn DE, Ayad A. Drug discovery: new models for industry-academic partnerships. Drug Discov Today. 2009; 14: 95-101.
229. SLAS Electronic laboratory neighborhood. Molecular Libraries Program review. 2012. Available from: http://www.eln.slas.org/story/1/52-the-nihs-molecular -libraries-program-whats-next (accessed 5 November 2012).
230. Frye S, Crosby M, Edwards T, Juliano R. US academic drug discovery. Nat Rev Drug Discov. 2011; 10: 409-10.
231. Jarvis L. Neuroscience outtakes part 2: Vanderbilt ' s jeff Conn on the role of academic labs. 2012. Avail -able from: http://cenblog.org/the-haystack/2012/03/ neuroscience-outtakes-part-2-vanderbilts-jeff-conn -on-the-role-of-academic-labs/ (accessed 5 November 2012).
232. World Pharma News. 2011. Lilly launches open innovation drug discovery platform. Available from: http:// www.worldpharmanews.com/lilly/1809-lilly-launches -open-innovation-drug-discovery-platform (accessed 5 November 2012).